<DOC>
	<DOCNO>NCT03081715</DOCNO>
	<brief_summary>This study evaluate safety PD-1 knockout engineer T cell treat advanced esophageal cancer . Blood sample also collect research purpose .</brief_summary>
	<brief_title>PD-1 Knockout Engineered T Cells Advanced Esophageal Cancer</brief_title>
	<detailed_description>This phase â…¡ clinical study ex-vivo knocked-out , expand , select PD-1 knockout-T cell autologous origin . 21 advanced esophageal cancer patient plan receive two cycle PD-1 knockout engineer T cell treatment . Biomarkers immunological marker collect analyzed well .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Histologically confirm recurrent metastatic esophageal cancer Measurable disease Progressed standard treatment ECOG performance status 02 Expected life span : &gt; = 3 month Toxicities prior treatment resolve . Washout period 4 week chemotherapy , 2 week target therapy Major organ function normally Women pregnant age contraception Willing able provide inform consent Other malignancy within 5 year prior entry study , expect treat nonmelanoma skin cancer cervical carcinoma situ Poor vasculature Disease central nervous system Bloodborne infectious disease , e.g . hepatitis B History mandatory custody psychosis psychological disease inappropriate treatment deem treat physician With immune disease , chronic use immunosuppressant steroids Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) Breastfeeding Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>immune checkpoint</keyword>
	<keyword>PD-1</keyword>
	<keyword>CRISPER</keyword>
	<keyword>autologous cell infusion</keyword>
</DOC>